Nasal Neomycin May Offer Virus Protection
April 29, 2024
-
3 min
In a study funded by the Melinda and Bill Gates Foundation, intranasal neomycin has shown potential in inducing broad-spectrum antiviral immunity in the upper respiratory tract. The drug's ability to trigger interferon-stimulated genes (ISGs) was highlighted, providing significant protection against upper respiratory infections in animal models. Neomycin, a commonly used antibiotic, demonstrated potential as a preventive strategy against respiratory viral infections in both animals and humans. The study suggests the possibility of optimizing neomycin to prevent viral diseases and their spread in human populations, especially in resource-limited communities. The study's findings present a novel approach to combat respiratory viral diseases, which could be beneficial for developing countries.
1. Neomycin demonstrates potential in inducing broad-spectrum antiviral immunity. 2. The drug triggers interferon-stimulated genes, providing protection against respiratory infections. 3. The study suggests optimizing neomycin for preventing viral diseases in human populations. 4. Neomycin showed promising results in a pilot human study involving intranasal application. 5. The approach presents a novel strategy to combat respiratory viral diseases.
Listen Tab content
